As of Jan 12, 2019 Surface Oncology Inc (NASDAQ:SURF) Shorts Decreased By 45.46%

Change of 45.46% for Surface Oncology Inc (NASDAQ:SURF)’s short interest was reported. In January was announced SURF’s total 594,100 short interest by FINRA. The 1.09 million previous shares are down with 45.46%. Former SURF’s position will need 3 days to restore. It has 231,900 average volume. 5.1% is Surface Oncology Inc float short.

Ticker’s shares touched $5.01 during the last trading session after 3.47% change.Surface Oncology, Inc. has volume of 62,973 shares. Since January 12, 2018 SURF has 0.00% and is . SURF the S&P 500 by 0.00%.

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies.The firm is worth $138.69 million. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation 47.Currently it has negative earnings. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27.

For more Surface Oncology, Inc. (NASDAQ:SURF) news brought out recently go to:,,, or The titles are as follows: “Surface Oncology Promotes Jessica Fees to Senior Vice President, Finance and Business Operations – GlobeNewswire” brought out on December 17, 2018, “Xumo to Go International in 2019, Launch Linear OTT Channels in Six Countries – Nasdaq” on January 09, 2019, “Sunwing helps Canadians celebrate the New Year with savings of up to 40% on vacation packages – GlobeNewswire” with a publish date: December 28, 2018, “Surface Oncology to Present at the Baird 2018 Global Healthcare Conference – GlobeNewswire” and the last “Mid-Afternoon Market Update: U.S. Stocks Turn Negative After Fed Hikes Interest Rates; Dow Tumbles Over 300 Points – Nasdaq” with publication date: December 19, 2018.

Surface Oncology, Inc. (NASDAQ:SURF) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.